Combination of Topiramate and Empagliflozin is Considered a Good Option for the Treatment of Obesity

Combination of Topiramate(Conviban) and Empagliflozin(Jardiance) is Considered a Good Option for the Treatment of Obesity

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04043702

Enrollment

200

Registered

2019-08-02

Start date

2019-01-04

Completion date

2019-07-29

Last updated

2019-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

obesity, drug combination, empagliflozin(jardiance), topiramate(conviban)

Brief summary

The aim was to show if a combination of topiramate and empagliflozin have the greatest weight decreasing effect in comparison to each drug alone and to group with no treatment( control group). .

Detailed description

The aim was to show if a combination of topiramate and empagliflozin have the greatest weight decreasing effect in comparison to each drug alone and to group with no treatment( control group). Materials and methods 200 obese patients 4 groups. had been monitored in a private clinic, each group 50 patients number, with 35 females and 15 males who were already on treatment.

Interventions

DRUGThe intervention being studied

Intervention Other Names have not been specified

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

30 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

1. stable weight in the previous 6 months. 2. a sedentary lifestyle. 3. no history of diabetes mellitus. 4. taking medication that affects appetite, or weight within the past 6 months

Exclusion criteria

1. severe anemia 2. hypothyroidism and hyperthyroidism 3. Diabetes mellitus 4. moderate to severe liver or kidney disease 5. body mass index less than 30

Design outcomes

Primary

Measure	Time frame	Description
change in weight	6 months	weight measurement

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026